ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.605
      -0.21%
      Bitcoin
      65,196.16
      0.09%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mesoblast Limited (MESO)

      7. Mesoblast Limited (MESO) News

      MESO

      Mesoblast (MESO)

      Mesoblast Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MESO
      DateTimeSourceHeadlineSymbolCompany
      06/04/20238:21PMGlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
      05/30/20236:06AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MESOMesoblast Limited
      05/26/20237:57AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      05/26/20236:04AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      05/25/20237:28PMGlobeNewswire Inc.Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023NASDAQ:MESOMesoblast Limited
      05/24/20237:00AMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
      05/03/20238:22AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      04/27/20239:00PMGlobeNewswire Inc.Appendix 4C Quarterly Activity ReportNASDAQ:MESOMesoblast Limited
      04/27/20236:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      04/25/20238:47PMGlobeNewswire Inc.Mesoblast Completes Private PlacementNASDAQ:MESOMesoblast Limited
      04/04/20236:17AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MESOMesoblast Limited
      04/04/20236:06AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MESOMesoblast Limited
      03/24/20236:40AMEdgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:MESOMesoblast Limited
      03/21/20239:20PMGlobeNewswire Inc.FDA Schedules Pre-License Inspection of Remestemcel-L ManufacturingNASDAQ:MESOMesoblast Limited
      03/16/20236:04AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      03/08/202310:51AMDow Jones NewsMesoblast ADSs Rally as FDA Accepts Remestemcel-L ResubmissionNASDAQ:MESOMesoblast Limited
      03/08/20236:04AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      03/07/20237:03PMGlobeNewswire Inc.FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023NASDAQ:MESOMesoblast Limited
      02/28/20236:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      02/27/20235:13PMGlobeNewswire Inc.Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022NASDAQ:MESOMesoblast Limited
      02/27/20234:49PMGlobeNewswire Inc.DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)NASDAQ:MESOMesoblast Limited
      02/26/20237:38PMGlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
      02/22/20236:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      02/16/20236:16PMGlobeNewswire Inc.Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and TherapyNASDAQ:MESOMesoblast Limited
      02/14/20236:16AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      02/08/20236:09PMGlobeNewswire Inc.FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back PainNASDAQ:MESOMesoblast Limited
      02/01/20235:14PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
      02/01/202312:22PMDow Jones NewsMesoblast Shares Rise 11% After Resubmitting Biologics License ApplicationNASDAQ:MESOMesoblast Limited
      01/31/20236:30PMGlobeNewswire Inc.Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)NASDAQ:MESOMesoblast Limited
      01/31/20234:40AMGlobeNewswire Inc.Appendix 4C Quarterly Activity ReportNASDAQ:MESOMesoblast Limited
       Showing the most relevant articles for your search:NASDAQ:MESO